Copyright
©The Author(s) 2025.
World J Gastroenterol. Aug 14, 2025; 31(30): 110112
Published online Aug 14, 2025. doi: 10.3748/wjg.v31.i30.110112
Published online Aug 14, 2025. doi: 10.3748/wjg.v31.i30.110112
Table 2 Comparison of demographic characteristics, clinical and laboratory findings between relapse and non-relapse groups, n (%)
Characteristics | Relapse (n = 12) (40.0%) | Non-relapse (n = 18) (60.0%) | P value |
Age at onset of IBD (years), median (IQR) | 31.0 (21.5-34.8) | 31.5 (22.0-37.8) | 0.5451 |
Female/male | 4 (33.3)/8 (66.7) | 9 (50.0)/9 (50.0) | 0.3672 |
Smoking status | |||
Current-smokers | 3 (25.0) | 4 (22.2) | 0.9993 |
Ex-smokers | 3 (25.0) | 5 (27.8) | |
Non-smokers | 6 (50.0) | 9 (50.0) | |
Family history of IBD | 3 (25.0) | 3 (16.7) | 0.6603 |
BMI (kg/m2), median (IQR) | 23.2 (20.3-25.8) | 23.7 (20.4-31.6) | 0.6391 |
Total disease duration (months), median (IQR) | 193.5 (89.3-270.8) | 167.5 (69.5-237.5) | 0.4651 |
Duration of remission before 5-ASA treatment withdrawal (months), median (IQR) | 152.0 (26.0-206.5) | 122.0 (15.3-172.3) | 0.3911 |
Follow-up time from 5-ASA withdrawal (months), median (IQR) | 23.5 (14.3-67.3) | 29.0 (17.3-61.3) | 0.6021 |
Disease extension | |||
Proctitis | 3 (25.0) | 3 (16.7) | 0.6003 |
Left-sided UC | 7 (58.3) | 14 (77.8) | |
Extensive UC | 2 (16.7) | 1 (5.6) | |
Extra-intestinal manifestations | 5 (41.7) | 9 (50.0) | 0.6542 |
Previous medications | |||
5-ASA tablet | 9 (75.0) | 16 (88.9) | 0.6223 |
5-ASA granule | 2 (16.7) | 0 (0.0) | 0.1523 |
5-ASA enema | 7 (58.3) | 11 (61.1) | 0.9993 |
5-ASA suppository | 2 (16.7) | 3 (16.7) | 0.9993 |
Sulfasalazine | 1 (8.3) | 0 (0.0) | 0.4003 |
Steroids | 6 (50.0) | 3 (16.7) | 0.1023 |
Thiopurine | 2 (16.7) | 1 (5.6) | 0.5483 |
Biologic agents | 1 (8.3) | 1 (5.6) | 0.9993 |
Steroid dependence | 2 (16.7) | 1 (5.6) | 0.5483 |
Withdrawal 5-ASA formula | |||
5-ASA tablet | 9 (75.0) | 16 (88.9) | 0.3643 |
5-ASA granule | 2 (16.7) | 0 (0.0) | 0.1523 |
5-ASA enema | 7 (58.3) | 11 (61.1) | 0.9993 |
5-ASA suppository | 2 (16.7) | 4 (22.2) | 0.9993 |
Baseline CRP (mg/L), median (IQR) | 5.0 (5.0-5.0) | 5.0 (4.2-5.0) | 0.9171 |
Hemoglobin (g/dL), median (IQR) | 13.0 (12.0-13.0) | 13.0 (12.0-13.7) | 0.4191 |
Albumin (g/dL), median (IQR) | 4.0 (4.0-4.0) | 4.0 (4.0-4.5) | 0.1091 |
Baseline eMayo subscore, median (IQR) | 1.0 (1.0-1.8) | 1.0 (1.0-1.3) | 0.8191 |
Baseline pMayo score, median (IQR) | 5.0 (5.0-5.0) | 5.0 (4.2-5.0) | 0.6621 |
- Citation: Atay A, Ergul M, Ozturk O, Acun KC, Cagir Y, Durak MB, Yuksel I. Outcomes of 5-aminosalicylates withdrawal due to non-adherence in ulcerative colitis patients: A step toward evaluating intermittent therapy. World J Gastroenterol 2025; 31(30): 110112
- URL: https://www.wjgnet.com/1007-9327/full/v31/i30/110112.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i30.110112